Last reviewed · How we verify
Short course MDR-TB treatment regimen — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Short course MDR-TB treatment regimen (Short course MDR-TB treatment regimen) — Medecins Sans Frontieres, Netherlands.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Short course MDR-TB treatment regimen TARGET | Short course MDR-TB treatment regimen | Medecins Sans Frontieres, Netherlands | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Short course MDR-TB treatment regimen CI watch — RSS
- Short course MDR-TB treatment regimen CI watch — Atom
- Short course MDR-TB treatment regimen CI watch — JSON
- Short course MDR-TB treatment regimen alone — RSS
Cite this brief
Drug Landscape (2026). Short course MDR-TB treatment regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/short-course-mdr-tb-treatment-regimen. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab